Skip to main content
. 2023 Nov 21;15(23):5502. doi: 10.3390/cancers15235502

Table 5.

The association between biomarkers of systemic inflammation combined with the occurrence of irAEs and progression-free survival and overall survival in all patients. Bold/italics represent statistically significant associations in this table and others.

Progression-Free Survival Overall Survival
Without irAE With irAE HR (95% CI)
p
Without irAE With irAE HR (95% CI)
p
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
SIPS 0 7.6 (2.7–23.3) 14.7 (5.3-n/r) 0.57 (0.36–0.91)
0.015
14.0 (2.8–5.3) 34.3 (18.9-n/r) 0.40 (0.24–0.67)
0.001
1 3.6 (1.8–13.6) 19.5 (7.1–45.4) 0.38 (0.22–0.64)
<0.001
8.2 (3.0–21.5) 23.6 (12.3-n/r) 0.40 (0.24–0.69)
0.001
2 1.6 (0.8–4.0) 8.1 (7.5–28.8) 0.26 (0.11–0.64)
0.003
2.9 (1.5–9.2) 16.7 (7.5–33.2) 0.35 (0.16–0.81)
0.013
HR (95% CI)
p
1.75 (1.43–2.14)
<0.001
1.15 (0.78–1.69)
0.479
1.67 (1.37–2.04)
<0.001
1.53 (1.03–2.28)
0.037
White Cell Count ≤11.0 × 109/L 4.6 (1.8–16.4) 15.6 (5.9–45.4) 0.50 (0.35–0.72)
<0.001
10.1 (4.1–28.2) 32.2 (14.3-n/r) 0.43 (0.29–0.63)
<0.001
>11.0 × 109/L 1.6 (0.9–6.0) 19.6 (7.5-n/r) 0.27 (0.14–0.51)
<0.001
4.1 (1.7–11.8) 25.5 (7.5-n/r) 0.28 (0.14–0.53)
<0.001
HR (95% CI)
p
1.74 (1.26–3.40)
0.001
0.85 (0.45–1.62)
0.621
1.80 (1.30–2.49)
<0.001
1.05 (0.53–2.07)
0.896
Neutrophil Count ≤7.5 × 109/L 11.0 (6.0–14.9) 20.4 (15.6–27.1) 0.54 (0.38–0.78)
0.001
10.7 (4.5–31.0) 32.2 (14.3-n/r) 0.46 (0.31–0.68)
<0.001
>7.5 × 109/L 3.3 (1.6–5.2) 17.9 (19.6–28.8) 0.25 (0.13–0.47)
<0.001
4.1 (1.6–10.4) 25.5 (7.5-n/r) 0.26 (0.13–0.49)
<0.001
HR (95% CI)
p
2.11 (1.54–2.91)
<0.001
0.83 (0.44–1.57)
0.560
2.02 (1.46–2.78)
<0.001
1.06 (0.54–2.09)
0.868
Albumin ≥35 g/L 6.0 (1.7–23.0) 17.1 (5.9-n/r) 0.48 (0.32–0.73)
0.001
11.0 (4.6–32.6) 43.9 (19.2-n/r) 0.35 (0.22–0.56)
<0.001
<35 g/L 2.5 (1.2–5.9) 14.3 (5.9–26.5) 0.35 (0.22–0.57)
<0.001
4.7 (1.7–11.7) 16.7 (8.0–32.6) 0.42 (0.26–0.67)
<0.001
HR (95% CI)
p
1.97 (1.43–2.72)
<0.001
1.53 (0.89–2.61)
0.123
1.88 (1.37–2.59)
<0.001
2.30 (1.29–4.10)
0.005